AbbVie, BigHat partner to discover next-generation therapeutic antibodies
The research collaboration will leverage BigHat’s artificial intelligence and machine learning (AI/ML) guided Milliner platform and AbbVie’s expertise…
AQEMIA, Sanofi ink $140m research collaboration deal for small molecules
06 Dec 23Under the terms of this arrangement, the French pharmatech firm will use its deep physics and generative AI…
Lilly’s Verzenio fails to improve overall survival in Phase 3 breast cancer trial
06 Dec 23A comparison of the intent-to-treat population at eight years of follow-up with MONARCH 3 revealed that women taking…
Roche’s Inavolisib combo meets primary endpoint in Phase 3 breast cancer trial
06 Dec 23The trial achieved progression-free survival (PFS) and showed a statistically significant and clinically meaningful improvement against palbociclib and…
Oxford Properties starts work on Ionis Pharmaceuticals’ Carlsbad campus expansion
06 Dec 23The expansion marks a continuation of the established partnership between Oxford and Ionis, which began with Oxford's acquisition…
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836
06 Dec 23OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of…
Odyssey Therapeutics Announces $101 Million Series C Financing
06 Dec 23Financing led by Ascenta Capital with participation from new and existing investors; Dr. Lorence Kim joins board of…
Roche to acquire US biotechnology company Carmot for up to $3.1bn
05 Dec 23Through the acquisition, Roche will get access to Carmot’s portfolio of incretins, including its lead asset CT-388, along…
Merck licenses Abbisko’s pimicotinib in deal worth up to $605.5m
05 Dec 23Under the agreement, Merck has the license to commercialise products comprising or containing CSF-1R inhibitor for all indications…
Absci, AstraZeneca partner to develop AI-based oncology candidate
05 Dec 23The partnership combines AstraZeneca's expertise in oncology R&D with Absci's Integrated Drug Creation platform to expedite the discovery…